Skip to Main Content

Try STAT+ TODAY

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot Ed Silverman

STAT Plus: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Outside vendors are used to help patients obtain drugs for free from patient assistance programs run by drug makers or foundations.

Politics Rachel Cohrs

Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government

Pharmalot Ed Silverman

STAT Plus: NIH rejects bid to cut a cancer drug’s price by sidestepping patents

Pharmalot Ed Silverman

STAT Plus: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

Politics Helen Branswell, Rachel Cohrs and Damian Garde

STAT Plus: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

All Coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax breaks in the semiconductor package

advertisement

Pharmalot Ed Silverman

STAT Plus: Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children disappoint

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research

Pharmalot Ed Silverman

STAT Plus: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

Pharmalot Ed Silverman

STAT Plus: Here’s why there aren’t many cheap, generic versions of pricey inhalers

Politics John Wilkerson

STAT Plus: Califf criticizes insurers for doing too little on drug research

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Alzheimer’s group starts lobbying for Medicare to cover new drug; U.S. judge seems sympathetic to abortion-pill challenge

Pharmalot Ed Silverman

STAT Plus: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug

Politics Rachel Cohrs

STAT Plus: Medicare explains how it will choose drugs for negotiation

Politics John Wilkerson

STAT Plus: Would the federal government defer to states to regulate PBMs?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biden administration to fine drugmakers for price hikes on 27 meds; Dems push pharmacy chains over access to abortion pill

Politics Rachel Cohrs

STAT Plus: Biden administration to fine manufacturers of 27 medicines for price hikes

First Opinion Brian Finrow, Aleks Engel and Srinivas Akkaraju

STAT Plus: Drug developers navigating ‘biology’s century’ need a model. We made one

Pharmalot Ed Silverman

STAT Plus: Democratic lawmakers press pharmacy chains on abortion pill access

Politics John Wilkerson

STAT Plus: PhRMA chief dings health insurers over drug prices at their own conference

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Novo to cut some insulin prices by up to 75%; Veterans Administration to cover new Alzheimer’s treatment

Pharmalot Ed Silverman

STAT Plus: Novo Nordisk to lower insulin prices by up to 75% amid growing pressure

Pharmalot Ed Silverman

STAT Plus: Veterans Health Administration will cover the newest Alzheimer’s drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Biogen exec who quarterbacked Aduhelm leaves; Pfizer to buy Seagen for $43 billion

Pharma Adam Feuerstein

STAT Plus: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion

Pharma Adam Feuerstein

STAT Plus: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion